SynthesisInternational ophthalmology2026
The Efficacy and Safety of Recombinant Human Nerve Growth Factor (rhNGF) in Patients With Dry Eye Disease: A Systematic Review and Meta-analysis.
Synthesis in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDry eye disease (DED) is a multifactorial condition affecting the ocular surface. Recombinant human nerve growth factor (rhNGF) has emerged as a potential new treatment for neurosensory dysfunction. The aim of this study is to evaluate the efficacy and safety of rhNGF in patients with DED.
methodsA comprehensive search of six online databases-Medline, CENTRAL, Web of Science, Ovid Medline, ClinicalTrials.gov, and Google Scholar-was conducted to identify randomized controlled trials (RCTs) evaluating the efficacy and safety of rhNGF in patients with dry eye disease, focusing on outcomes such as tear production, ocular surface integrity, and adverse events.
resultsThe results demonstrated that rhNGF significantly improved tear production compared with placebo, as measured by the Schirmer test (MD = 3.84; 95% CI: 2.17-5.51; P < 0.00001; I
conclusionrhNGF shows promise for improving tear production in patients with dry eye disease, as demonstrated by significant improvement in Schirmer test results. However, evidence for broader clinical efficacy remains limited, with other outcomes showing non-significant or heterogeneous findings. Current data are based on a small number of trials, indicating the need for larger, well-designed studies to clarify the therapeutic role and safety profile of rhNGF in dry eye disease.
Indexed as
Identifiers
42053663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.